Galera Therapeutics uses a proprietary platform to create novel agents that amplify the efficacy of existing breast cancer drugs, aiming to boost tumor response and enable lower dosages. Their preclinical pipeline focuses on combination candidates that synergize with chemotherapy, hormonal, and targeted therapies, offering pharmaceutical partners and clinicians enhanced treatment options.
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current breast cancer treatments often have limited anti‑cancer efficacy and can cause significant side effects, leading to suboptimal outcomes for many patients.
Solution
Galera Therapeutics applies a first‑in‑class scientific platform to develop novel agents that boost the effectiveness of existing breast cancer therapies. By targeting mechanisms that enhance tumor response, the company aims to increase treatment potency while potentially reducing required dosages of standard drugs. Their approach integrates advanced molecular design and preclinical validation to create combination candidates that can be integrated into current treatment regimens. The goal is to deliver therapies that improve clinical response rates and overall survival for breast cancer patients.
Target Audience
Primary customers are pharmaceutical companies and oncology research groups seeking combination partners, as well as clinicians treating breast cancer patients who could benefit from enhanced therapeutic options.
Features
- Proprietary technology platform focused on augmenting the anti‑cancer activity of approved breast cancer drugs
- Development of combination agents designed to synergize with standard chemotherapy, hormonal, and targeted therapies
- Preclinical models that assess enhanced tumor control and safety profiles compared with monotherapy
- Strategy to enable dose reduction of existing treatments, potentially lowering toxicity
- Pipeline of novel compounds positioned for integration into established breast cancer treatment protocols